Tags: Drug.

SB-649868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development this drug for sleep disorders is one of two such compounds currently in development the other being Merck & Co’s suvorexant.

SB649868_structure.png
ATC prefix
None
IUPAC name
N-([(2S)-1-([5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl)-2-piperidinyl]methyl)-4-benzofurancarboxamide
PubChem
25195495

Loading...

This page contains content from the copyrighted Wikipedia article "SB-649868"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.